Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study.

Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study.

Am J Gastroenterol. 2019 Mar 05;:

Authors: Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, Cuker T, Farkash R, Hoyda A, Granot T, Avni-Biron I, Lahat A, Goldin E, Grisaru-Granovsky S

Abstract
OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs’ (VDZ) safety profile in pregnancy is not established.
DESIGN: Data of 330 consecutive pregnancies with IBD was prospectively collected.
RESULTS: Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn’s disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy.
CONCLUSIONS: Although further study is needed, VDZ appears of low risk during pregnancy.

PMID: 30920987 [PubMed – as supplied by publisher]

PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920987?dopt=Abstract